

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 4)\***

**Biomea Fusion, Inc.**

---

**(Name of Issuer)**

**Common Stock**

---

**(Title of Class of Securities)**

**09077A106**

---

**(CUSIP Number)**

**Neb Obradovic**  
**Cormorant Asset Management, L.P., 200 Clarendon Street, 52nd Floor**  
**Boston, MA, 02116**  
**857-702-0386**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**10/22/2025**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 09077A106**

Name of reporting person

1

Cormorant Global Healthcare Master Fund, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4 WC  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

477,791.00

Owned by

Sole Dispositive Power

Each

9

0.00

Reporting

Person

With:

Shared Dispositive Power

10

477,791.00

Aggregate amount beneficially owned by each reporting person

11  
477,791.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12   
Percent of class represented by amount in Row (11)

13  
0.69 %

Type of Reporting Person (See Instructions)

14  
PN

## SCHEDULE 13D

**CUSIP No.** 09077A106

Name of reporting person

1  
Cormorant Global Healthcare GP, LLC

Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

Number of 7 Sole Voting Power

Shares Beneficially Owned by Each Reporting Person With: 0.00  
 Shared Voting Power  
 8  
 477,791.00  
 Sole Dispositive Power  
 9  
 0.00  
 Shared Dispositive Power  
 10  
 477,791.00  
 Aggregate amount beneficially owned by each reporting person  
 11  
 477,791.00  
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)  
 12  
  
 Percent of class represented by amount in Row (11)  
 13  
 0.69 %  
 Type of Reporting Person (See Instructions)  
 14  
 OO

## SCHEDULE 13D

**CUSIP No.** 09077A106

1 Name of reporting person  
 Cormorant Private Healthcare Fund III LP  
 Check the appropriate box if a member of a Group (See Instructions)  
 2  
 (a)  
 (b)  
 3 SEC use only  
 Source of funds (See Instructions)  
 4  
 WC  
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)  
 5  
  
 Citizenship or place of organization  
 6  
 DELAWARE  
 Sole Voting Power  
 7  
 Number of Shares Beneficially Owned by Each Reporting Person With: 0.00  
 Shared Voting Power  
 8  
 456,855.00  
 Sole Dispositive Power  
 9  
 0.00  
 Shared Dispositive Power  
 10  
 456,855.00  
 11 Aggregate amount beneficially owned by each reporting person

456,855.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.66 %

Type of Reporting Person (See Instructions)

14

PN

### SCHEDULE 13D

**CUSIP No.** 09077A106

Name of reporting person

1

Cormorant Private Healthcare GP III, LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

456,855.00

Owned by

Each

Sole Dispositive Power

Reporting 9

0.00

Person

With:

Shared Dispositive Power

10

456,855.00

Aggregate amount beneficially owned by each reporting person

11

456,855.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.66 %

Type of Reporting Person (See Instructions)

14

OO

# SCHEDULE 13D

CUSIP No. 09077A106

1 Name of reporting person  
Cormorant Asset Management, LP  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

6 Citizenship or place of organization  
DELAWARE

7 Sole Voting Power  
0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power  
950,000.00

9 Sole Dispositive Power  
0.00

10 Shared Dispositive Power  
950,000.00

11 Aggregate amount beneficially owned by each reporting person  
950,000.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)  
1.37 %

14 Type of Reporting Person (See Instructions)  
PN

# SCHEDULE 13D

CUSIP No. 09077A106

1 Name of reporting person  
Chen Bihua  
Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
Source of funds (See Instructions)

4 AF  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 UNITED STATES

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With:

8 110,792.00  
Shared Voting Power

9 950,000.00  
Sole Dispositive Power

10 110,792.00  
Shared Dispositive Power

10 950,000.00

11 Aggregate amount beneficially owned by each reporting person

11 1,060,792.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

13 Percent of class represented by amount in Row (11)

13 1.53 %

14 Type of Reporting Person (See Instructions)

14 IN

## SCHEDULE 13D

### Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock  
Name of Issuer:

(b) Biomea Fusion, Inc.

Address of Issuer's Principal Executive Offices:

(c) 1599 INDUSTRIAL ROAD, SAN CARLOS, CALIFORNIA , 94070.

**Item 1 Comment:** This Amendment No. 4 to Schedule 13D (this "Amendment") relates to Common Stock of Biomea Fusion, Inc., a Delaware corporation (the "Issuer" or the "Company"). The address of the principal executive offices of the Issuer is 1599 Industrial Road, San Carlos, CA 94070. This Amendment is being filed by the Reporting Persons to amend the Schedule 13D that was filed on April 30, 2021, as amended by Amendment No. 1 filed on April 3, 2023, Amendment No. 2 filed on July 22, 2025, and Amendment No. 3 filed on October 10, 2025 (as so amended, the "Schedule 13D"). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meaning as in the Schedule 13D.

### Item 2. Identity and Background

(a) Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Private Healthcare Fund III, LP Cormorant Private Healthcare GP III, LLC Cormorant Asset Management, LP Bihua Chen

(b) 200 Clarendon Street, 52nd Floor Boston, MA 02116

(f) Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware  
Cormorant Private Healthcare Fund III, LP - Delaware Cormorant Private Healthcare GP III, LLC - Delaware

Item 5. Interest in Securities of the Issuer

(a) See Items 7-13 of the cover page and Item 2.

See Items 7-13 of the cover page and Item 2. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in a Prospectus filed by the Issuer on October 7, 2025 that there would be 69,322,377 shares of Common Stock outstanding following the closing of a public offering described therein, and (ii) a statement in a Current Report on Form 8-K filed by the Issuer on October 7, 2025 reporting that the public offering was expected to close on October 8, 2025. The shares reported for Bihua Chen reflect shares of Common Stock that she has the right to receive within 60 days upon the exercise of stock options granted to her in her capacity as a director of the Issuer.

(b) The Reporting Persons effected the following transactions in the Company's Common Stock in the 60 day period beginning on the date requiring the filing of this Schedule 13D: (i) on October 22, 2025, the Reporting Persons sold an aggregate of 820,872 shares of Common Stock in open-market transactions at prices ranging from \$1.42 to \$1.58 per share (weighted-average price \$1.48 per share); and (ii) on October 23, 2025, the Reporting Persons sold an aggregate of 1,800,000 shares of Common Stock in open-market transactions at prices ranging from \$1.35 to \$1.51 per share (weighted-average price \$1.41 per share). The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price of the transactions reported in this Schedule 13D.

(c) Not applicable.

(d) As a result of the transactions described herein, as of October 22, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Issuer's outstanding Common Stock.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cormorant Global Healthcare Master Fund, LP

Signature: /s/ CORMORANT GLOBAL HEALTHCARE  
MASTER FUND, LP By: Cormorant Global  
Healthcare GP, LLC, its General Partner  
Name/Title: By: Bihua Chen, Managing Member  
Date: 10/24/2025

Cormorant Global Healthcare GP, LLC

Signature: /s/ Bihua Chen  
Name/Title: By: Bihua Chen, Managing Member  
Date: 10/24/2025

Cormorant Private Healthcare Fund III LP

Signature: /s/ CORMORANT PRIVATE HEALTHCARE  
FUND III, LP By: Cormorant Private Healthcare  
GP III, LLC, its General Partner  
Name/Title: By: Bihua Chen, Managing Member  
Date: 10/24/2025

Cormorant Private Healthcare GP III, LLC

Signature: /s/ Bihua Chen  
Name/Title: By: Bihua Chen, Managing Member  
Date: 10/24/2025

Cormorant Asset Management, LP

Signature: /s/ CORMORANT ASSET MANAGEMENT, LP  
By: Cormorant Asset Management GP, LLC, its  
General Partner  
Name/Title: By: Bihua Chen, Managing Member  
Date: 10/24/2025

Chen Bihua

Signature: /s/ Bihua Chen  
Name/Title: Bihua Chen

Date:

10/24/2025